(NASDAQ:ETNB – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor ...

Inc. (NASDAQ:ETNB – Get Free Report)’s share price dropped 3.7% during trading on Tuesday . The company traded as low as $7.50 and last traded at $7.50. Approximately 101,562 shares were traded during ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...

On Friday, 89bio Inc (ETNB) stock saw a modest uptick, ending the day at $7.94 which represents a slight increase of $0.91 or 12.94% from the prior close of $7.03. The stock opened at $7.03 and ...

The Inducement Grant has been granted pursuant to the Company's 2023 Inducement Plan (the "Plan”). The Inducement Grant was ...

On Thursday, 89bio Inc (ETNB) stock saw a decline, ending the day at $7.03 which represents a decrease of $-0.58 or -7.62% from the prior close of $7.61. The stock opened at $7.67 and touched a low of ...

MASH is a culmination of steatosis, inflammation, and fibrosis, and is also associated with comorbidities such as obesity and ...

89Bio, Inc. (NASDAQ:ETNB) is a biopharmaceutical company focused on developing therapies for liver and cardio-metabolic diseases. The company's lead candidate, pegozafermin (pegoza), is being ...

89Bio, Inc. (NASDAQ:ETNB), with a market capitalization of $925 million and current share price of $7.88, is a biopharmaceutical company focused on developing therapies for liver and cardio-metabolic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpointsSAN FRANCISCO, Nov. 15, 2024 ...